Data presented at CROI in Boston was recently published in Science detailing the use of a depot injection of a new integrase inhibitor that protected macaques from simian/human immunodeficiency virus infection for at least 6 weeks. PrEP is currently limited to Truvada with ongoing studies of vaginal rings implanted with NNRTI's and topical agents including tenofovir gel. The Truvada prevention study results were notable for lesser protection with low medication adherence. A depot approach would alleviate this potential. The studies remain limited to animals.